Scott Gottlieb, MD Profile picture
Senior Fellow @AEI. Partner @NEA. Contributor @CNBC. 23rd Commissioner of @US_FDA. Boards: @Pfizer @Illumina @AetionInc @TempusLabs @MountSinaiNYC
eDo Profile picture Ross Grayson, MPH, CIH Profile picture John Saunders Profile picture m rose Profile picture Norris Battin Profile picture 87 added to My Authors
Jan 22 4 tweets 3 min read
My Op Ed. To reform CDC, we should focus it more squarely on its mission in communicable diseases; moving many other public health mandates to agencies that already oversee broad programs in same areas, getting analytical work closer to operational agents

washingtonpost.com/opinions/2023/… A thoughtful article documenting how CDC didn’t comply with law congress passed, and in 2010 update its information technology systems as Congress prescribed, by my @aei colleague Yuval Levin. Challenges CDC faces today were set in motion many years ago

aei.org/op-eds/bidens-…
Jan 9 8 tweets 2 min read
🧵In the past, I've raised concerns with Twitter related to the safety of me and others, and threats being made on the platform. This included direct as well as specific threats. Sometimes it included statements that I believed were purposely false and inflammatory 👇 The selective disclosure of my private communications with Twitter stokes the threat environment. So does actions that empower people who’ve shown little restraint when it comes to purposeful vitriol. It instigates more menacing dialogue, with potentially serious consequences 👇
Dec 13, 2022 10 tweets 4 min read
🧵If we lose chance to create modern framework for FDA regulation of diagnostics, FDA won't walk away from issue. If VALID doesn’t pass, FDA will move ahead under existing authorities; which aren't well suited to challenge of promoting safety, innovation

raps.org/news-and-artic… We should expect FDA to act on its own if VALID doesn't pass Congress. Easiest most efficient way? Would be to end agency's historical enforcement discretion. FDA could simply clarify that all LDTs are now subject to active regulation as medical devices fda.gov/medical-device…
Nov 27, 2022 6 tweets 2 min read
🧵What happened in 3/22 when Omicron hit Hong Kong, illustrates challenge China faces

Hong Kong like China had low vaccination rates; especially among elderly

In face of much more contagious variant, low pre-existing immunity in HK was devastating 1/x

bloomberg.com/news/features/… When Omicron hit Hong Kong, only 72% of residents were fully vaccinated, 30% boosted

By comparison, in China, 88% were fully vaccinated, 40% boosted; a figure that hasn't changed much

Hong Kong, unlike China, deployed vaccines that have proven more effective against Omicron 2/x
Nov 24, 2022 6 tweets 3 min read
🧵 Important new study shows high frequency of virus co-infection and species spillover among animals bats; with 12 viruses shared among different bat species, which in turn facilitates virus recombination and reassortment, and new genetic diversity 1/3

biorxiv.org/content/10.110… h/t @MichaelWorobey

Fantastic work from Mang Shi and scientific colleagues:

"A novel recombinant #SARS-like coronavirus...with only five amino acid differences between its receptor-binding domain sequence and that of the earliest sequences of SARS-CoV-2" in Yunnan, #China 2/3
Nov 23, 2022 4 tweets 2 min read
#FoodSafety 🦃🥘🍽️

The @CDCgov estimates 48 million people get sick from food borne diseases every year in US, many outbreaks occur around #Thanksgiving. Here are a few cooking practices to keep your family safe and healthy this holiday season ⬇️ today.com/health/top-rea… 👉🏻 Always wash your food, hands, counters, and cooking tools.

👉🏻 Keep raw foods to themselves. Germs can spread from one food to another.

👉🏻 Foods need to get hot and stay hot. Heat kills germs.

👉🏻 Put perishable food in the fridge right away.

fda.gov/consumers/free…
Nov 5, 2022 5 tweets 4 min read
Will be interesting to track development of this psychedelic by Lusaris and @rfsquared and how regulators approach compound. Sublingual, fast acting formulations of controlled substances have faced close scrutiny in past owing to risk of diversion, abuse thedalesreport.com/psychedelics/p… Image Recent controversies around at home Ketamine and history related to sublingual formulations of opioids could inform how @US_FDA considers issues related to drugs with characteristics like the new compound being developed by @LusarisTx @rfsquared
psychiatrictimes.com/view/virtually…
Nov 5, 2022 13 tweets 5 min read
🧵Will discuss decisions made during Covid that impacted families; some of hardest were school closures. In WSJ I wrote in 2020 here wsj.com/articles/schoo… and here wsj.com/articles/want-… that states should open schools. Many like my state CT made it top priority, others didn't My argument Summer 2020, after first wave, was: "Schools should open in the fall. It’s critical for meeting the educational and social needs of children. But local officials should have the discretion to take tailored actions to help keep children safe" wsj.com/articles/schoo…
Oct 27, 2022 6 tweets 2 min read
We shouldn’t underestimate how much the predictable backlash to the failed 2021 mandate that businesses require employees to get vaccinated, using a contorted reading of OSHA provisions, is going to - regrettably - bleed into broader opposition to vaccines thelancet.com/journals/lance… My 2021 comments on that rule

Oct 19, 2022 4 tweets 2 min read
🧵Vaccines for Children (VFC) is federally funded program that "provides vaccines at no cost to children who might not otherwise be vaccinated because of inability to pay.” This program has long been used to help families in need get access to vaccines
cdc.gov/vaccines/progr… Under VFC, CDC buys vaccines at discount to distribute to registered providers. For CDC to add a vaccine to VFC, it must be 'recommended' by ACIP, then CDC. This allows costs to be covered by same program used to broaden access to other childhood vaccines cdc.gov/vaccines/progr…
Oct 16, 2022 10 tweets 5 min read
🧵 My article with Mark McClellan in Journal of the American Medical Association on the VALID Act - a major provision before Congress that modernizes FDA oversight of diagnostic tests, promoting safety and innovation

Here’s why passage is critical:

jamanetwork.com/journals/jama-… 1/x Background: When I was FDA commissioner, the agency delivered to Congress comprehensive technical assistance on which VALID is based; as I discussed at Friends of Cancer Research in 2017:

insidehealthpolicy.com/daily-news/got…

I wrote this as well when VALID was introduced in March 2020. 2/x
Oct 13, 2022 7 tweets 4 min read
My article w/Mark McClellan in @JAMAHealthForum on three major provisions needed to modernize @US_FDA's oversight of dietary supplements, cosmetics, and diagnostic tests. We must advance these efforts to improve opportunities for patients. Here’s how…1/x
jamanetwork.com/journals/jama-… ImageImageImage 80% of US consumers report using dietary supplements; most mistakenly believe FDA reviews or tests products before they reach market. No such requirements exist and manufacturers often don't disclose ingredients of new products to regulators, consumers 2/x pewtrusts.org/en/research-an…
Aug 17, 2022 8 tweets 2 min read
CDC's proposed reforms and the self-analysis fueling these changes are the right diagnosis and prescription. They represent bold, comprehensive commitments that will go a long way to address many of the system challenges that plagued CDC for many years 1/x washingtonpost.com/health/2022/08… Among notable features: A self awareness that CDC's culture is academic in orientation when CDC must be much more operationally focused, emphasizing execution over publications. This bleeds into how CDC puts out information, issues guidance. It must be more consumer facing 2/x
Aug 9, 2022 4 tweets 2 min read
There’s a lot of precedent for intradermal delivery of vaccines to extend supply in public health emergencies. It was done for yellow fever and Ebola. This is a reasonable move based on solid data. Challenges will be local delivery issues. Good planning can help mitigate them 1/x The study supporting intradermal inoculation found similar safety and immunogenicity using 20% of full dose 28 days apart to standard formulation of MVA, concluding that intradermal vaccination could be used to increase number of available doses 5-fold 2/x sciencedirect.com/science/articl…
Jul 23, 2022 4 tweets 2 min read
WHO’s hesitation in making declaration earlier, when scope of crisis was already obvious, was an openly political gesture. The reality is the practical impact of declaration is muted, because WHO has marginalized itself. Nonetheless, a good move by Tedros to act with conviction. Washington Post writing on the prior WHO decision not to make the declaration: “Monkeypox cases surge as WHO stops short of declaring a global emergency”
washingtonpost.com/health/2022/06…
Jul 22, 2022 4 tweets 2 min read
Ukraine has been experiencing an outbreak of type-2 circulating vaccine-derived poliovirus since Oct 2021. A national catch-up vaccination campaign targeting ~140,000 children under 6 yrs old who missed routine polio doses began Feb to arrest the outbreak bit.ly/3RT3wv8 Two children with acute flaccid paralysis (AFP) have tested positive for cVDPV2 and the virus has been detected in 19 asymptomatic contacts. Millions have been displaced since the war began, including the 2 positive cases whose whereabouts cannot be traced bit.ly/3PtJcix
Jun 29, 2022 9 tweets 4 min read
🧵Since 2002, health agencies have been tasked with ensuring that there’s enough smallpox vaccine in strategic national stockpile to meet U.S. health security needs

Yet only 100 million doses of the smallpox vaccine ACAM2000 are currently available, not enough for every American 100 million doses of ACAM2000 doesn’t meet the CDC’s claim that “The Strategic National Stockpile (SNS) has stockpiled enough smallpox vaccine to vaccinate every person in the United States,” a pledge that President Bush made in 2002 amidst concerns about the risk of bioterrorism
Jun 12, 2022 8 tweets 3 min read
🧵It’s time to modernize regulation of clinical tests

VALID Act is bipartisan framework, reflecting broad stakeholder input. It's a historic opportunity to advance innovation, benefit patients

Link to HELP Committee
help.senate.gov/chair/newsroom…

or Burr PR
burr.senate.gov/2022/5/senator… US was tragically behind in testing early in pandemic. VALID is critical step toward making us better prepared to stand up testing in future public health emergencies, and FDA is key to making sure tests for emerging pathogens are accurate and reliable

cnbc.com/2020/01/26/op-…
May 4, 2022 11 tweets 6 min read
New: House E&C Committee releases package to reauthorize FDA user fee agreements

Lots of good ideas in here

Link to legislative text below, summary attached

I’ll post my views on specific sections here as I go through bill.

Some initial thoughts: 1/n

republicans-energycommerce.house.gov/wp-content/upl… ImageImageImageImage On closely watched provisions on accelerated approval

Congress preserves but tightens, by streamlining FDA ability to withdraw AA drugs that don’t achieve + confirmatory studies

But maintains ability of companies to have that decision go to FDA adcom and have public docket ImageImageImageImage
Apr 30, 2022 4 tweets 2 min read
New from Sigal lab on protection offered by prior B1 infection or vaccination against B4/B5

Finds:

Much B4/B5 escape in previously B1 infected but unvaxxed

Situation much better in vaccinated B1 breakthrough cases

Escape is much less, and original B1 elicits more immunity Sigal concludes: ‘My guess based on this: BA.4/BA.5 escape, while not as dramatic as Omicron escape from vax or Delta immunity, is enough to cause trouble and lead to an infection wave. But not likely to cause much more severe disease than the previous wave, especially in vaxxed’
Apr 29, 2022 4 tweets 1 min read
It isn't point that CMS will (for now) use its newly divined "authority" sparingly. Point is CMS asserted - without legislation - that it doesn't consider a class of drugs, which includes many big breakthroughs, "reasonable and necessary" just by virtue of its legal FDA pathway State Medicaid plans have long wanted, and tried, to restrict access to accelerated approval drugs as a category, as part of cost saving strategies

Past R and D administrations blocked these attempts

CMS decision will open door to the policies

This will erode equitable access